Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Finding Retinal Biomarkers in Alzheimer's Disease

Authors not listed

Assistance Publique - Hôpitaux de Paris · 2021

Abstract

CSF Alzheimer's disease (AD) biomarkers are the only one that reflect both Aβ and tau pathologies. There is increasing evidence for the presence of AD abnormalities in the retina of AD patients. Recent studies showed that they can be detected in living patients. Thus, retinal AD-linked abnormalities might be used as alternative diagnostic biomarkers for AD. FIREBALZ study aims at identifying and validating retinal biomarkers for the diagnosis of Alzheimer's disease. The study will include 160 patients in whom LP is indicated for assessment of CSF AD biomarkers according to French health authority (HAS) recommendations. Those patients will undergo a detailed neuro-ophtalmologic evaluation including retinal layers thickness evaluation (optical coherence tomography). Univariate and multivariate analyses will be performed to test diagnostic properties of retinal parameters as compared to current diagnostic criteria including CSF biomarkers and logistic regression models will be used.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-01 MST

Cite this

APA
Anonymous. (2021). Finding Retinal Biomarkers in Alzheimer's Disease. <em>Assistance Publique - Hôpitaux de Paris</em>. https://clinicaltrials.gov/study/NCT05067010
Vancouver
Anonymous. Finding Retinal Biomarkers in Alzheimer's Disease. Assistance Publique - Hôpitaux de Paris. 2021.
BibTeX
@misc{anon2021Findin, title = {Finding Retinal Biomarkers in Alzheimer's Disease}, author = {Anonymous}, journal = {Assistance Publique - Hôpitaux de Paris}, year = {2021}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings